Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Healthcare Biotechnology

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Post by Viking2233on Jan 08, 2025 9:39am

182 Views

Post# 36393931

Ontario Sites

So management news releases they have ethics approval at two Ontario sites but require additional internal approvals before dosing starts.

I am not sure how to react. I guess it provides additional credibility to the trial but they still are not dosing.

I do not see the markets reacting, I certainly do not see the short sellers covering.

Lets dive a little deeper here.

Arch has been dosing for 10 months at 5 turkish sites. These sites would see approximately 1,000 potential patients annually, thats 5,000 patients or about 420 potential patients per month.

Now the trial goal is to dose 260 patients.

260 divided by 5,000 = .05% doding rate, that is less the 1% of patients are deemed suitable for this trial

The fact they have hidden the news thst trial completion date was extended from Feb 2025 to August 2025 and continue to add these Canadian sites suggest the duitable selection criteria is much lower then .05%

The good news is there have been no adverse reactions reported.

The bad news is we have been left in the dark regarding any progress made in the past 10 months of dosing.

Communication from this management team is an issue and continues to be an issue coupled with the fact this company behaves like a private company and feels no need to update shareholders.

We had one analyst covering the company from Raymond James and he left the firm, so not sure we have any analyst coverage. Toronto has an analyst who covrrs the sector and is top 10 rated and has never heard of Arch, how can thst be when CEO of Arch is Toronto based.

Toronto is the Financial hub of Canada and Bay street is the main destination for institutional investors. How is it that we have 0% institutional ownership?

2 years ago Arch was valued 30% higher then today. How can that be? In that 2 years we announced an increased dosage study that demondtrated the drug is tolerated at a dose 4 times higher. We announced and international phase 2 AKI trial and have been dosing for 10 months at 6 locations with zero negative reactions reported. We announced our re-purpised drug Cilastatin will be used in a phase 2 Pontiac trial headed by University of Calgary in 2025.

So how can Arch be valued 30% lower then 2 yesrs ago? How can it be that Arch is not covered by any analysts? How can be that Arch has zero institutional ownership?

Does anyone have any thoughts why this is?